NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $681.58 which represents a decrease of $-11.65 or -1.68% from the prior close of $693.23. The stock opened at $705.34 and ...

Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...